108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
格拉斯哥预后评分可作为新诊断多发性骨髓瘤患者临床结局的预后因素
Authors Li S, Zhang L, Liu S, Liang Z , Wang W, Wang Y, Liang Y
Received 26 May 2025
Accepted for publication 5 September 2025
Published 13 September 2025 Volume 2025:18 Pages 12699—12711
DOI https://doi.org/10.2147/JIR.S539706
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Felix Marsh-Wakefield
Shuzhen Li,1,2,* Limei Zhang,1,2,* Shutong Liu,3,* Zhijian Liang,1,2 Weida Wang,1,2 Yun Wang,1,2 Yang Liang1,2
1Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 2Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, People’s Republic of China; 3Department of Hematology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yang Liang, Department of Hematologic Oncology, Sun Yat-Sen University Cancer, State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People’s Republic of China, Email liangyang@sysucc.org.cn Yun Wang, Department of Hematologic Oncology, Sun Yat-Sen University Cancer, State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People’s Republic of China, Email wangyun@sysucc.org.cn
Purpose: The Glasgow Prognostic Score (GPS), a systemic inflammation-based prognostic model incorporating C-reactive protein (CRP) and serum albumin levels, has been widely validated in solid tumors and several hematologic malignancies. However, its prognostic value in newly diagnosed multiple myeloma (NDMM) remains unclear. This study aimed to evaluate the association between GPS and survival outcomes in NDMM patients.
Patients and Methods: We retrospectively analyzed a real-world cohort of 865 NDMM patients. Patients were stratified based on GPS, and overall survival (OS) and progression-free survival (PFS) were assessed by using Kaplan-Meier analysis. Cox proportional hazards models were used to determine the independent prognostic significance of GPS, adjusting for confounding factors. To compare the prognostic stratification capacity of GPS to its two modified variants, the same Kaplan-Meier analysis was applied to evaluate both the modified Glasgow Prognostic Score (mGPS) and the hypersensitivity-modified Glasgow Prognostic Score (Hs-mGPS). Quantitative comparisons utilized area under the curve (AUC) values derived from time-dependent Receiver Operating Characteristic (ROC) analysis.
Results: A higher GPS was significantly associated with inferior OS and PFS in NDMM patients. Multivariate analysis confirmed that GPS was an independent prognostic factor after adjusting for disease stage and other clinical variables. Additionally, patients with elevated GPS scores presented with more advanced disease stages, as reflected by higher Durie-Salmon and International Staging System (ISS) classifications. And GPS exerts better prognostic stratification capacity than mGPS and Hs-mGPS.
Conclusion: The baseline GPS at the time of diagnosis is an independent prognostic factor that negatively relates to the MM patient survival, for which GPS may serve as a supplement tool in risk stratification upon the primary medical assessment.
Keywords: multiple myeloma, survival, inflammation model, prognosis
1Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 2Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, People’s Republic of China; 3Department of Hematology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yang Liang, Department of Hematologic Oncology, Sun Yat-Sen University Cancer, State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People’s Republic of China, Email liangyang@sysucc.org.cn Yun Wang, Department of Hematologic Oncology, Sun Yat-Sen University Cancer, State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People’s Republic of China, Email wangyun@sysucc.org.cn
Purpose: The Glasgow Prognostic Score (GPS), a systemic inflammation-based prognostic model incorporating C-reactive protein (CRP) and serum albumin levels, has been widely validated in solid tumors and several hematologic malignancies. However, its prognostic value in newly diagnosed multiple myeloma (NDMM) remains unclear. This study aimed to evaluate the association between GPS and survival outcomes in NDMM patients.
Patients and Methods: We retrospectively analyzed a real-world cohort of 865 NDMM patients. Patients were stratified based on GPS, and overall survival (OS) and progression-free survival (PFS) were assessed by using Kaplan-Meier analysis. Cox proportional hazards models were used to determine the independent prognostic significance of GPS, adjusting for confounding factors. To compare the prognostic stratification capacity of GPS to its two modified variants, the same Kaplan-Meier analysis was applied to evaluate both the modified Glasgow Prognostic Score (mGPS) and the hypersensitivity-modified Glasgow Prognostic Score (Hs-mGPS). Quantitative comparisons utilized area under the curve (AUC) values derived from time-dependent Receiver Operating Characteristic (ROC) analysis.
Results: A higher GPS was significantly associated with inferior OS and PFS in NDMM patients. Multivariate analysis confirmed that GPS was an independent prognostic factor after adjusting for disease stage and other clinical variables. Additionally, patients with elevated GPS scores presented with more advanced disease stages, as reflected by higher Durie-Salmon and International Staging System (ISS) classifications. And GPS exerts better prognostic stratification capacity than mGPS and Hs-mGPS.
Conclusion: The baseline GPS at the time of diagnosis is an independent prognostic factor that negatively relates to the MM patient survival, for which GPS may serve as a supplement tool in risk stratification upon the primary medical assessment.
Keywords: multiple myeloma, survival, inflammation model, prognosis